Abstract
Aim:
To construct the recombinant vectors carrying interleukin (IL)-28A, IL-28B and IL-29 cDNAs and express them in human A549 cells, and analyze their antiviral activity in vesicular stomatitis virus (VSV)-infected human immortalized amnion epithelial cell line (WISH cells).
Methods:
Total cell RNA was extracted from human peripheral blood mononuclear cells (PBMC) activated with poly I:C. The cDNAs encoding human IL-28A, IL-28B, and IL-29 were amplified by reverse-transcription polymerase chain reaction (RT-PCR) and inserted into pcDNA3.1/ V5-His-TOPO vectors. These recombinant vectors were transfected into human A549 cells by a liposome-mediated gene transfer method. Semiquantitative RT-PCR and Western blotting were used to detect the mRNA and protein expression of IL-28A, IL-28B, and IL-29. The antiviral activity of IL-28A, IL-28B, and IL-29 was determined by a cytopathic effect reduction assay on WISH cells using VSV as a challenge virus.
Results:
The DNA sequences of the inserts were identical to the published sequences encoding IL-28A, IL-28B, and IL-29 in GenBank. It was demonstrated that IL-28 A, IL-28B, and IL-29 genes were markedly transcribed in transfected cells. Expression of all 3 interleukins in A549 cells was confirmed by Western blot analysis. IL-28 and IL-29 expressed by A549 cells, like interferon (IFN) α-2b, were able to protect WISH cells against VSV infection.
Conclusion:
IL-28 and IL-29 cDNAs were successfully cloned and expressed in eukaryotic cells via transfection with pcDNA3.1/V5-His-TOPO-IL-28/IL-29. Transfection with this vector produced a specific antiviral activity similar to that of IFN-α, which will provide a new tool for the functional study of these cytokines in humans.
Similar content being viewed by others
Article PDF
References
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63–8.
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69–77.
Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and l interferon as in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796–805.
Renauld JC . Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003; 3: 667–76.
Kotenko SV . The family of IL10-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev 2002; 13: 223–40.
Dumoutier L, Renauld JC . Viral and cellular interleukin-10 (IL-10)-related cytokines: from structures to functions. Eur Cytokine Netw 2002; 13: 5–15.
Langer JK, Cutrone EC, Kotenko SV . The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004; 15: 33–48.
Li M, He S . IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004; 10: 620–5.
Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC . Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem J 2003; 370: 391–6.
Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB . Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 2004; 22: 929–79.
Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H . The interleukin-10 family of cytokines. Trends Immunol 2002; 23: 89–96.
Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC . Role of the interleukin-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/IFN-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004; 279: 32269–74.
Ebner S, Neyer S, Hofer S, Nussbaumer W, Romani N, Heufler C . Generation of large numbers of human dendritic cells from whole blood passaged through leukocyte removal filters: an alternative to standard buffy coats. J Immunol Methods 2001; 252: 93–104.
Kozak M . An analysis of 5′-noncoding sequences from 699 ver tebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125–48.
Kozak M . Pushing the limits of the scanning mechanism for initiation of translation. Gene 2002; 299: 1–34.
Sambrook J, Fritsch EF, Maniatis T . Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 2001.
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ . Basic local alignment search tool. J Mol Biol 1990; 215: 403–10.
Schwickerath O, Brouns G, Thrasher A, Kinnon C, Roes J, Casimir C . Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD. J Gene Med 2004; 6: 603–15.
Edelstein ML, Abedi MR, Wixon J, Edelstein RM . Gene therapy clinical trials worldwide 1989–2004: an overview. J Gene Med 2004; 6: 597–602.
Oku N, Yamazaki Y, Matsuura M, Sugiyama M, Hasegawa M, Nango M . A novel non-viral gene transfer system: polycation liposomes. Adv Drug Deliv Rev 2001; 52: 209–18.
Choi WJ, Kim JK, Choi SH, Park JS, Ahn WS, Kim CK . Low toxicity of cationic lipid-based emulsion for gene transfer. Biomaterials 2004; 25: 5893–903.
Song D, Wang HL, Wang S, Zhang XH . 5-Hydroxytryptamine-induced proliferation of pulmonary artery smooth muscle cells are extracellular signal-regulated kinase pathway dependent. Acta Pharmacol Sin 2005; 26: 563–7.
Familletti PC, Rubinstein S, Pestka S . A convenient and rapid cytopathic effect inhibition assay for interferon. Methods Enzymol 1981; 78: 387–94.
Osterlund P, Veckman V, Siren J, Klucher KM, Hiscott J, Matikainen S, et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005; 79: 9608–17.
Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289: G960–8.
Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M . Bio logical activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109–18.
Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, Vlotides G, et al. SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 2005; 331: 543–8.
Robek MD, Boyd BS, Chisari FV . Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851–4.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from the Li Ka Shing Foundation, Hong Kong, China (No C0200001), the Major State Basic Research Program of China (973 Program) (No 2001CB510009), the National Natural Science Foundation of China (No 30471601), the Planned Science and Technology Project of Guangdong Province, China (No 2003B31502), and the National Natural Science Foundation of Guangdong Province, China (No 04106122).
Rights and permissions
About this article
Cite this article
Li, Mc., Wang, Hy., Wang, Hy. et al. Liposome-mediated IL-28 and IL-29 expression in A549 cells and antiviral effect of IL-28 and IL-29 on WISH cells. Acta Pharmacol Sin 27, 453–459 (2006). https://doi.org/10.1111/j.1745-7254.2006.00292.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2006.00292.x
Keywords
This article is cited by
-
Purification and characterization of prokaryotically expressed human interferon-λ2
Biotechnology Letters (2007)